News | Heart Valve Technology | April 17, 2024

CPR-Therapeutics, Inc. Names Mike Black as Chief Strategy Officer

Mike Black

Mike Black


April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer.

CPR Therapeutics, Inc. is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is one of the leading causes of sudden death worldwide and there are currently no devices more effective than manual chest compressions. Intact survival after cardiac arrest is below 10% in most communities.

Dave Gaddy, CPR Therapeutic’s CEO said “We could not be more excited to have Mike’s expertise. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. He was CEO of Advanced Circulatory Systems Inc. (ACSI), one of the few start-ups to innovate significantly in CPR. He went on to be Vice President of Global Customer Experience at ZOLL Medical, a leading strategic company in EMS that acquired ACSI in 2015.”

Asked to share his perspective on CPR-T, Mike responded “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Dr. Paradis, CPR-T’s Founder and Chief Medical Officer added: “Mike is a great fit for helping our start-up company take on one of medicine’s most intractable problems – improving the efficacy of CPR. I genuinely believe our chances for success go up significantly having Mike in this important role.”

For more information: www.cprtherapeutics.com


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now